HLXA SEC filings, in plain English
Everything Helix Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Exhibit 99.1 to an 8-K of MoonLake Immunotherapeutics (Nasdaq: MLTX): the August 10, 2026 press release reporting Week 16 topline results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis, together with Q2 2026 financial results. Why it matters: The percentages are absolute response rates in one treatment arm with no placebo comparison disclosed — the placebo-controlled comparison is still blinded — so the size of the treatment effect cannot be read from this release. The lead indication's BLA has not yet been submitted.
What changed: Q2 2026 10-Q of MoonLake Immunotherapeutics (Nasdaq: MLTX). Cash and equivalents rose to $477,905 thousand at June 30, 2026 from $334,517 thousand at December 31, 2025, with short-term marketable debt securities of $59,125 thousand, taking total assets to $573,947 thousand from $424,433 thousand. Long-term debt rose to $99,514 thousand from $74,100 thousand and total liabilities to $145,752 thousand. Why it matters: The company funded a $131.5 million half-year loss and still grew cash, through roughly $255 million of additional paid-in capital and $25 million of incremental debt. Operating spend is running at about $62 million a quarter.
What changed: MoonLake Immunotherapeutics, the Helix Acquisition Corp successor, reported that on July 10, 2026 the underwriters of its previously announced public offering of Class A ordinary shares — and, for certain investors, pre-funded warrants in lieu of shares — exercised in full their option to purchase an additional 1,500,000 ordinary shares. The exercise produced additional gross proceeds of $30.0 million before underwriting discounts, commissions and offering expenses, and the closing of the issuance and sale of the option shares occurred on July 14, 2026. Why it matters: Full exercise of the greenshoe means the offering was oversubscribed at the pricing level, so demand rather than distress drove this raise — a distinction that matters at a clinical-stage de-SPAC where most equity issuance is defensive. The $30.0 million of extra gross proceeds extends the runway ahead of clinical milestones, at the cost of 1,500,000 more shares plus the pre-funded warrants issued in the base deal, which convert on payment of a nominal exercise price and should be counted as outstanding for dilution purposes.
What changed: MoonLake Immunotherapeutics, the successor to Helix Acquisition Corp, will hold its 2026 annual general meeting on Thursday, June 4, 2026 at 8:00 a.m. Eastern Time in person at the offices of Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, record date April 9, 2026, with 72,852,170 Class A Ordinary Shares outstanding and one vote each. Items include a Class I director election and an equity incentive plan proposal. The Class A shares closed at $16.52 on Nasdaq on April 1, 2026. Simon Sturge resigned from the Board effective February 28, 2026. Why it matters: An in-person New York meeting rather than a webcast limits practical participation for a shareholder base spread across a 72.9 million share float. The substantive item is the incentive plan proposal, which at a $16.52 reference price sets the value of every option and stock award granted from here. The Helix trust was released at the de-SPAC, so the shares carry no floor; a board resignation three months before the meeting is the governance detail to track.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.